Stockscreener 앱 받기
26.86
4.04%
-1.13
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Biotherapeutics (ARQT) Stock Analysis: Riding High On A 24% Potential Upside - DirectorsTalk Interviews
ARQT|Arcutis Biotherapeutics Inc|Price:27.860|Chg%:+0.510 - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Balance Sheet - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Cash Flow - TradingKey
Arcutis Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics Inc (ARQT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arcutis: Intense Competition, Costs, Slow Growth Merit Downgrade To Hold (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup - ChartMill
Enterprise value to revenue forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Understanding Momentum Shifts in (ARQT) - Stock Traders Daily
META_TITLE_QUOTE - Yahoo Finance
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet - Yahoo Finance
The Bull Case For Arcutis Biotherapeutics (ARQT) Could Change Following FDA Acceptance Of Infant ZORYVE sNDA - webull.com
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum - ChartMill
Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,730 common shares worth $127,269.30 - Bitget
Arcutis Biotherapeutics director sells $127,284 in stock - Investing.com UK
Form 4 Arcutis Biotherapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (ARQT) director receives RSUs and stock options - Stock Titan
Arcutis Biotherapeutics director sells $127,284 in stock By Investing.com - Investing.com UK
Arcutis Biotherapeutics (ARQT) director trades stock under 10b5-1 plan - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup - ChartMill
Arcutis Biotherapeutics Appoints Chris Peetz to Board of Directors to Drive Growth and Innovation in Immuno-Dermatology 1 – Minichart - Minichart
Arcutis Biotherapeutics Enhances Board Governance with Christopher Peetz Joining as Tenth Director - Kalkine Media
Arcutis Biotherapeutics appoints Chris Peetz to board By Investing.com - Investing.com South Africa
Arcutis appoints Christopher Peetz to its board as Class III director - TradingView
Arcutis Biotherapeutics (Nasdaq: ARQT) names Chris Peetz to its board - Stock Titan
Arcutis Biotherapeutics, Inc. Appoints Christopher Peetz to its Board of Directors, Effective July 15, 2026 - marketscreener.com
Arcutis Biotherapeutics appoints Chris Peetz to board - Investing.com
Arcutis appoints Chris Peetz to its Board to bo... - Pluang
Arcutis Expands Board of Directors with Appointment of Chris Peetz - The Manila Times
Press Release: Arcutis Expands Board of Directors With Appointment of Chris Peetz - Moomoo
Attovia Therapeutics appoints John Smither to board By Investing.com - Investing.com Australia
Arcutis to report Q2 2026 financial results on August 5 - scanx.trade
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 - The Manila Times
Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 4730 common shares - Stock Titan
Arcutis schedules Aug. 5 webcast for its business update - Stock Titan
FDA accepts Arcutis application for infant eczema treatment By Investing.com - Investing.com Nigeria
Arcutis gets FDA review for Zoryve 0.05% label expansion - MSN
Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies - The Globe and Mail
Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy? - simplywall.st
BREAKING: US FDA Sets PDUFA for Roflumilast Cream 0.05% in Infants With AD - The Dermatology Digest
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Receives FDA Acceptance for Zoryve Cream - GuruFocus
FDA accepts Arcutis application for infant eczema treatment - Investing.com
Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants - Moomoo
FDA accepts Arcutis' application to expand ZORY... - Pluang
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - The Manila Times
2.44%
0.02%
자본화:
|
볼륨(24시간):